Сурункали юрак етишмовчилиги ва бўлмачалар фибрилляцияси билан оғриган беморларда антикоагулянтларнинг тутган ўрни (Адабиётлар шархи)
Kalit so'zlar:
бўлмачалар фибрилляцияси, сурункали юрак етишмовчилиги, нтикоагулянтларAnnotatsiya
Мақолада бўлмачалар фибрилляцияси (БФ) ва сурункали юрак етишмовчилиги (СЮЕ) билан боғлиқ ритмни назорат қилишга доир асосий муаммоларни охирги тадқиқотлар ва клиник тавсиялар асосида муҳокама қилинди. БФ ва ХСН билан беморларда антикоагулянт терапиясининг хусусиятлари очиб берилган. Икки ҳолатнинг биргаликда мавжудлигида қон кетиш хавфига оид антикоагулянтларнинг хавфсизлик профилига алоҳида эътибор қаратилиши кўрсатиб ўтилган
Библиографические ссылки
1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for thediagnosis and management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS).Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.
2. Karnik AA, Gopal DM, Ko D, et al. Epidemiology of Atrial Fibrillation and Heart Failure: A Growing and Important Problem. Cardiol Clin.2019;37(2):119-29. DOI:10.1016/j.ccl.2019.01.001.
3. Терещенко С.Н., Галявич А.С., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083 [Tereshchenko SN, Galyavich AS, Uskach TM, et al. 2020 Clinical practice guidelines for chronic heart failure. Rossiiskii kardiologicheskii zhurnal. 2020;25(11):4083 (in Russian)].DOI:10.15829/1560-4071-2020-4083.
4. Pandey A, Kim S, Moore C, et al. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation.JACC Heart Fail. 2017;5(1):44-52. DOI:10.1016/j.jchf.2016.09.016.
5. Zhao L, Wang WYS, Yang X. Anticoagulation in atrial fibrillation with heart failure. Heart Fail. Rev. 2018;23(4):563-71. DOI:10.1007/s10741-018-9693-0
6. Banerjee A, Taillandier S, Olesen JB, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail. 2012;14(3):295-301.DOI:10.1093/eurjhf/hfs005
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin inpatients with atrial fibrillation. New Engl J Med. 2009;361:1139-51. DOI:10.1056/NEJMoa0905561
8. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104. DOI:10.1056/NEJMoa1310907.
9. Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116(05):975-86. DOI:10.1160/TH16-05-0403
10. McMurray JJ, Ezekowitz JA, Lewis BS, et al. Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial. Circ Heart Fail. 2013;6(3):451-60. DOI:10.1161/CIRCHEARTFAILURE.112.000143.
11. Osaka Y, Ono Y, Tao S, et al. Feasibility and safety of uninterrupted apixaban in patients undergoing radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol. 2020;58(1):35-41. DOI:10.1007/s10840-019-00563-6
